Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study.

ABSTRACT: Multiple myeloma (MM) is a complex hematological malignancy of clonal plasma cells driven by alterations to the chromosomal material leading to uncontrolled proliferation in the bone marrow. Ethnic and racial disparities persist in the prevalence, diagnosis, management, and outcomes of MM. These disparities are multifaceted and intersect with various factors, including demographics, geography, socioeconomic status, genetics, and access to healthcare. This study utilized the openFDA human drug adverse events (AEs) to analyze global data pertaining to MM patients and patterns of treatment-related AEs. We identified ten most frequently used drugs and drug regimens in six distinct regions, including North America (NA), Europe (EU), Asia (AS), Africa (AF), Oceania (OC), and Latin America & the

SUBMITTER: Jaberi-Douraki M 

PROVIDER: S-EPMC11661995 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature